494 Shares in Eli Lilly and Company (LLY) Purchased by Vantage Financial Partners Ltd. Inc.

Vantage Financial Partners Ltd. Inc. bought a new position in shares of Eli Lilly and Company (NYSE:LLY) in the second quarter, according to the company in its most recent filing with the SEC. The firm bought 494 shares of the company’s stock, valued at approximately $494,000.

Other institutional investors have also recently made changes to their positions in the company. Airain ltd acquired a new stake in shares of Eli Lilly and during the 2nd quarter worth about $567,000. Buckingham Asset Management LLC increased its position in shares of Eli Lilly and by 21.3% during the 2nd quarter. Buckingham Asset Management LLC now owns 3,232 shares of the company’s stock worth $266,000 after purchasing an additional 568 shares in the last quarter. BSW Wealth Partners increased its position in shares of Eli Lilly and by 0.6% during the 2nd quarter. BSW Wealth Partners now owns 4,774 shares of the company’s stock worth $393,000 after purchasing an additional 27 shares in the last quarter. Sumitomo Life Insurance Co. increased its position in shares of Eli Lilly and by 4.4% during the 2nd quarter. Sumitomo Life Insurance Co. now owns 32,507 shares of the company’s stock worth $2,675,000 after purchasing an additional 1,370 shares in the last quarter. Finally, Mirador Capital Partners LP increased its position in shares of Eli Lilly and by 5.3% during the 2nd quarter. Mirador Capital Partners LP now owns 12,280 shares of the company’s stock worth $1,011,000 after purchasing an additional 619 shares in the last quarter. Institutional investors and hedge funds own 75.66% of the company’s stock.

Eli Lilly and Company (LLY) opened at $83.51 on Friday. The company has a market cap of $91.53 billion, a PE ratio of 20.33, a PEG ratio of 1.83 and a beta of 0.34. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.01 and a current ratio of 1.38.

Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.03 by $0.02. The company had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The company’s revenue for the quarter was up 9.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.88 EPS. equities analysts predict that Eli Lilly and Company will post 4.22 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Wednesday, November 15th will be paid a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.49%. The ex-dividend date is Tuesday, November 14th. Eli Lilly and’s payout ratio is 98.58%.

LLY has been the subject of a number of recent analyst reports. TheStreet upgraded shares of Eli Lilly and from a “c+” rating to a “b+” rating in a research report on Tuesday, July 25th. Berenberg Bank reiterated a “buy” rating and set a $98.00 target price on shares of Eli Lilly and in a research report on Friday, August 4th. Deutsche Bank AG reiterated a “buy” rating and set a $91.00 target price (up previously from $90.00) on shares of Eli Lilly and in a research report on Monday, July 17th. Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 target price for the company in a research report on Monday, July 17th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $96.00 target price (up previously from $93.00) on shares of Eli Lilly and in a research report on Thursday, July 13th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $89.76.

TRADEMARK VIOLATION NOTICE: “494 Shares in Eli Lilly and Company (LLY) Purchased by Vantage Financial Partners Ltd. Inc.” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://www.com-unik.info/2017/11/04/494-shares-in-eli-lilly-and-company-lly-purchased-by-vantage-financial-partners-ltd-inc.html.

In related news, major shareholder Lilly Endowment Inc sold 190,000 shares of Eli Lilly and stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $82.53, for a total transaction of $15,680,700.00. Following the transaction, the insider now owns 123,682,287 shares of the company’s stock, valued at approximately $10,207,499,146.11. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 770,000 shares of company stock worth $64,669,850 in the last three months. 0.20% of the stock is owned by insiders.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

What are top analysts saying about Eli Lilly and Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Eli Lilly and Company and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit